Skoči na glavni sadržaj

Izvorni znanstveni članak

https://doi.org/10.11613/BM.2020.010706

Analytical verification and comparison of chromogenic assays for dabigatran, rivaroxaban and apixaban determination on BCSXP and STA Compact Max analysers

Ivana Ćelap orcid id orcid.org/0000-0002-3982-5777 ; Department of Clinical Chemistry, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Sandra Margetić ; Department of Clinical Chemistry, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Marija Brčić ; Department of Clinical Chemistry, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Roman Mihić ; Department of Clinical Chemistry, Sestre milosrdnice University Hospital Center, Zagreb, Croatia


Puni tekst: engleski pdf 221 Kb

str. 110-117

preuzimanja: 260

citiraj


Sažetak

Introduction: The aim of the study was to perform analytical verification and comparison of chromogenic assays for determination of dabigatran,
rivaroxaban and apixaban concentration on BCSXP and STA Compact Max analysers.
Materials and methods: Precision, linearity, measurement uncertainty estimation and determination of limit of blank, limit of determination and limit of quantification were calculated. Analytical performance specifications were set according to manufacturer specifications and literature data on between laboratory variability. Comparison of the methods was done using Bland-Altman and Passing-Bablok regression analysis.
Results: Obtained results have shown acceptable precision on STA Compact Max only for dabigatran (CV = 3.5%) at lower concentration level comparing to manufacturer declaration (CV = 3.6%). On BCSXP, the highest coefficient of variation has been shown for apixaban (6.1%) at lower concentration level. Within laboratory precision was not met on STA Compact Max for all assays. Bland-Altman analysis has shown statistically significant bias for dabigatran (23.2%, 95%CI 11.2 – 35.3; P < 0.001) and apixaban (8.4%, 95%CI 1.2 – 15.6; P = 0.023). Passing-Bablok regression analysis has shown systematic and proportional deviation between methods for rivaroxaban (y = 6.52 (2.94 to 11.83) + 0.84 (0.80 to 0.89) x.
Conclusion: Chromogenic assays for dabigatran, rivaroxaban and apixaban on BCSXP and STA Compact Max analysers are shown as methods with satisfactory long-term analytical performance specifications for determination of direct oral anticoagulants in clinical laboratories. However, we cannot recommend interchangeable use because of the significant bias between assays.

Ključne riječi

chromogenic assay; dabigatran; rivaroxaban; apixaban; method comparison

Hrčak ID:

234146

URI

https://hrcak.srce.hr/234146

Datum izdavanja:

15.2.2020.

Posjeta: 738 *